Table 1 Patient baseline characteristics
Placebo (N = 31) | Rebamipide 2% (N = 31) | Rebamipide 4% (N = 32) | |
|---|---|---|---|
Male (%) | 25 (81) | 26 (84) | 26 (81) |
Age (mean ± SD) (%) | 60 ± 9 | 61 ± 12 | 62 ± 9 |
ECOG PS (PS = 0) (%) | 28 (90) | 28 (90) | 28 (88) |
Primary site | |||
Oral cavity (%) | 2 (6) | 4 (13) | 4 (13) |
Nasopharynx (%) | 6 (19) | 7 (23) | 6 (19) |
Oropharynx (%) | 17 (55) | 14 (45) | 15 (47) |
Hypopharynx (%) | 5 (16) | 6 (19) | 6 (19) |
Larynx (%) | 1 (3) | 0 | 1 (3) |
Prior surgery for head and neck cancer (with prior surgery) (%) | 7 (23) | 7 (23) | 6 (19) |
TNM staging of primary tumor | |||
T1 | 6 (19) | 9 (29) | 4 (13) |
T2 | 14 (45) | 10 (32) | 15 (47) |
T3 | 7 (23) | 4 (13) | 5 (16) |
T4 | 4 (13) | 8 (26) | 8 (25) |
N0 | 7 (23) | 3 (10) | 3 (9) |
N1 | 8 (26) | 3 (10) | 8 (25) |
N2 | 13 (42) | 23 (74) | 20 (63) |
N3 | 3 (10) | 2 (6) | 1 (3) |
Radiation technique | |||
3D–CRT | 4 (13) | 9 (29) | 7 (22) |
IMRT | 27 (87) | 22 (71) | 25 (78) |